What is the impact of GOLD 2017 recommendations in primary care? &amp;ndash; a descriptive study of patient classifications, treatment burden and costs

Gayle, Alicia; Dickinson, Scott; Morris, Kevin; Poole, Chris; Mathioudakis, Alexander G.; Vestbo, Jørgen

doi:10.2147/copd.s173664

Cited by 25 publications

(23 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, it is anticipated that the newer GOLD classification will decrease the therapeutic burden of these patients without affecting their clinical outcomes. Application of GOLD 2017 criteria in a cross-sectional study involving over 19 000 patients from the UK Clinical Practice Research Datalink (CPRD) led to reclassification of 37% of all participants from groups C and D (according to GOLD 2013) to groups A and B [ 47 , 48 ]. Only 16% of all patients with COPD were classified as GOLD groups C or D according to GOLD 2017, compared to 54% according to GOLD 2013 [ 47 , 48 ].…”

Section: Copdmentioning

confidence: 99%

“…Application of GOLD 2017 criteria in a cross-sectional study involving over 19 000 patients from the UK Clinical Practice Research Datalink (CPRD) led to reclassification of 37% of all participants from groups C and D (according to GOLD 2013) to groups A and B [ 47 , 48 ]. Only 16% of all patients with COPD were classified as GOLD groups C or D according to GOLD 2017, compared to 54% according to GOLD 2013 [ 47 , 48 ]. A cross-sectional study in Poland involving 2597 patients with COPD, as identified by primary care physicians, confirmed that the application of GOLD 2017 leads to a decrease in patients allocated to GOLD groups C and D by 60% [ 49 ].…”

Section: Copdmentioning

confidence: 99%

See 1 more Smart Citation

Research highlights from the 2018 European Respiratory Society International Congress: airway disease

et al. 2019

Self Cite

View full text Add to dashboard Cite

The annual European Respiratory Society (ERS) International Congress (held in Paris in 2018) was once again a platform for discussion of the highest-quality scientific research, cutting-edge techniques and innovative new therapies within the respiratory field. This article discusses only some of the high-quality research studies presented at this year's Congress, with a particular focus on airway diseases including asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis and cough, as presented through Assembly 5 of the ERS (Airway Diseases: Asthma and COPD). The authors establish the key take-home messages of these studies, compare their findings and place them in the context of current understanding.

show abstract

Section: Copdmentioning

confidence: 99%

Section: Copdmentioning

confidence: 99%

Research highlights from the 2018 European Respiratory Society International Congress: airway disease

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…The expense of inhaler prescriptions skyrocketed after the ban of chlorofluorocarbon propellants in 2008, virtually eliminating all the generic inhalers from the market. The changes in the global initiative for chronic obstructive lung disease (GOLD) guidelines in 2017 [6] and the global initiative for asthma (GINA) guidelines in 2019 [7] are estimated to change the type and cost of inhaler prescriptions significantly.…”

Section: Introductionmentioning

confidence: 99%

Trends in Inhaler Prescriptions and Associated Cost in the United States From 2014 to 2018: An Analysis From the Medicare Part D Database

Thomas¹,

Haddad²,

Hoskere³

2021

Cureus

View full text Add to dashboard Cite

Introduction: Chronic obstructive pulmonary disease (COPD) and asthma constitute the majority of the pulmonary disease burden in the United States. Various kinds of inhalers are used for treating both these conditions, and Medicare is the biggest payer for them. We analyze the trend in prescriptions and associated expenses of various inhaler prescriptions from 2014 to 2018 using the Medicare part D database. Methods: Medicare part D data is analyzed for the years 2014-2018. Inhalers are grouped based on their drug class. The number of beneficiaries and the associated expenses for each inhaler and the groups were calculated separately and analyzed using statistical software. Results and Conclusion: Some 85 million beneficiaries received inhalers through Medicare part D over the four years. Medicare spent 50.5 billion US dollars on these prescriptions, which showed an increase of 130% users and 128% expenditure over the four years. Medicare's expense for inhaler prescriptions is growing and is expected to increase even more in the near future.

show abstract

“…Chronic obstructive pulmonary disease (COPD), a leading cause of death, disability and health-related expenditure globally, is characterised by chronic debilitating respiratory symptoms and acute exacerbations, that drive the adverse outcomes of the disease. [1][2][3][4] Both stable COPD and exacerbations are complex and heterogeneous, meaning that several distinct mechanistic pathways contribute to their development and progression. 5 6 While some of these pathways are well established, our understanding of the pivotal strengths and limitations of this study ► A holistic approach to a clinically pertinent question that could pump-prime clinical and translational research and facilitate the introduction of precision medicine interventions both for stable chronic obstructive pulmonary disease and exacerbations.…”

Section: Introductionmentioning

confidence: 99%

Prevalence and clinical implications of respiratory viruses in stable chronic obstructive pulmonary disease (COPD) and exacerbations: a systematic review and meta-analysis protocol

et al. 2020

Self Cite

View full text Add to dashboard Cite

IntroductionBoth stable chronic obstructive pulmonary disease (COPD) and acute exacerbations represent leading causes of death, disability and healthcare expenditure. They are complex, heterogeneous and their mechanisms are poorly understood. The role of respiratory viruses has been studied extensively but is still not adequately addressed clinically. Through a rigorous evidence update, we aim to define the prevalence and clinical burden of the different respiratory viruses in stable COPD and exacerbations, and to investigate whether viral load of usual respiratory viruses could be used for diagnosis of exacerbations triggered by viruses, which are currently not diagnosed or treated aetiologically.Methods and analysisBased on a prospectively registered protocol, we will systematically review the literature using standard methods recommended by the Cochrane Collaboration and the Grading of Recommendations Assessment, Development and Evaluation working group. We will search Medline/PubMed, Excerpta Medica dataBASE (EMBASE), the Cochrane Library, the WHO’s Clinical Trials Registry and the proceedings of relevant international conferences on 2 March 2020. We will evaluate: (A) the prevalence of respiratory viruses in stable COPD and exacerbations, (B) differences in the viral loads of respiratory viruses in stable COPD vs exacerbations, to explore whether the viral load of prevalent respiratory viruses could be used as a diagnostic biomarker for exacerbations triggered by viruses and (C) the association between the presence of respiratory viruses and clinical outcomes in stable COPD and in exacerbations.Ethics and disseminationEthics approval is not required since no primary data will be collected. Our findings will be presented in national and international scientific conferences and will be published in peer reviewed journals. Respiratory viruses currently represent a lost opportunity to improve the outcomes of both stable COPD and exacerbations. Our work aspires to ‘demystify’ the prevalence and clinical burden of viruses in stable COPD and exacerbations and to promote clinical and translational research.PROSPERO registration numberCRD42019147658.

show abstract

What is the impact of GOLD 2017 recommendations in primary care? – a descriptive study of patient classifications, treatment burden and costs

Cited by 25 publications

References 20 publications

Research highlights from the 2018 European Respiratory Society International Congress: airway disease

Research highlights from the 2018 European Respiratory Society International Congress: airway disease

Trends in Inhaler Prescriptions and Associated Cost in the United States From 2014 to 2018: An Analysis From the Medicare Part D Database

Prevalence and clinical implications of respiratory viruses in stable chronic obstructive pulmonary disease (COPD) and exacerbations: a systematic review and meta-analysis protocol

Contact Info

Product

Resources

About